• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.

作者信息

Shah N, Thall P F, Fox P S, Bashir Q, Shah J J, Parmar S, Lin P, Kebriaei P, Nieto Y, Popat U R, Hosing C M, Cornelison A, Shpall E J, Orlowski R Z, Champlin R E, Qazilbash M H

机构信息

Department of Stem Cell Transplantation and Cellular Therapy, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.

出版信息

Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27.

DOI:10.1038/leu.2015.54
PMID:25721897
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4785590/
Abstract
摘要
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9eeb/4785590/9f474c6afc94/nihms762984f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9eeb/4785590/9f474c6afc94/nihms762984f1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9eeb/4785590/9f474c6afc94/nihms762984f1.jpg

相似文献

1
Phase I/II trial of lenalidomide and high-dose melphalan with autologous stem cell transplantation for relapsed myeloma.来那度胺与大剂量美法仑联合自体干细胞移植治疗复发性骨髓瘤的I/II期试验
Leukemia. 2015 Sep;29(9):1945-8. doi: 10.1038/leu.2015.54. Epub 2015 Feb 27.
2
Chemotherapy plus lenalidomide versus autologous transplantation, followed by lenalidomide plus prednisone versus lenalidomide maintenance, in patients with multiple myeloma: a randomised, multicentre, phase 3 trial.来那度胺联合化疗与自体移植，随后来那度胺联合泼尼松与来那度胺维持治疗多发性骨髓瘤患者：一项随机、多中心、3 期试验。
Lancet Oncol. 2015 Dec;16(16):1617-29. doi: 10.1016/S1470-2045(15)00389-7. Epub 2015 Nov 17.
3
A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma.一项关于大剂量来那度胺和美法仑作为复发或难治性多发性骨髓瘤自体干细胞移植预处理的I期试验。
Biol Blood Marrow Transplant. 2017 Jun;23(6):930-937. doi: 10.1016/j.bbmt.2017.03.007. Epub 2017 Mar 8.
4
Autologous transplantation and maintenance therapy in multiple myeloma.自体移植和多发性骨髓瘤的维持治疗。
N Engl J Med. 2014 Sep 4;371(10):895-905. doi: 10.1056/NEJMoa1402888.
5
Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma.中剂量美法仑（100mg/m²）/硼替佐米/沙利度胺/地塞米松联合干细胞支持治疗难治性或复发性骨髓瘤患者。
Clin Lymphoma Myeloma. 2006 May;6(6):475-7. doi: 10.3816/CLM.2006.n.028.
6
Intravenous melphalan, thalidomide and prednisone in refractory and relapsed multiple myeloma.静脉注射美法仑、沙利度胺和泼尼松用于难治性和复发性多发性骨髓瘤
Eur J Haematol. 2006 Apr;76(4):273-7. doi: 10.1111/j.1600-0609.2005.00610.x.
7
Multiple myeloma in the elderly: when to treat, when to go to transplant.老年多发性骨髓瘤：何时治疗，何时进行移植。
Oncology (Williston Park). 2010 Oct;24(11):992-8.
8
Lenalidomide plus melphalan without prednisone for previously untreated older patients with multiple myeloma: a phase II trial.来那度胺联合美法仑，不使用泼尼松，治疗未经治疗的多发性骨髓瘤老年患者：一项 II 期试验。
Clin Lymphoma Myeloma Leuk. 2013 Feb;13(1):19-24. doi: 10.1016/j.clml.2012.08.009. Epub 2012 Nov 7.
9
[Hematopoietic stem cell transplantation for multiple myeloma].[多发性骨髓瘤的造血干细胞移植]
Rinsho Ketsueki. 2009 Oct;50(10):1420-6.
10
[High-dose chemotherapy and autologous stem cell transplantation in multiple myeloma patients--single center experience].[多发性骨髓瘤患者的大剂量化疗与自体干细胞移植——单中心经验]
Przegl Lek. 2011;68(2):78-81.

引用本文的文献

1
CFO: Calibration-free odds design for phase I/II clinical trials.无校准似然比设计在 I/II 期临床试验中的应用。
Stat Methods Med Res. 2022 Jun;31(6):1051-1066. doi: 10.1177/09622802221079353. Epub 2022 Mar 3.
2
Implementing the EffTox dose-finding design in the Matchpoint trial.在配对试验中实施EffTox剂量探索设计。
BMC Med Res Methodol. 2017 Jul 20;17(1):112. doi: 10.1186/s12874-017-0381-x.
3
High-dose gemcitabine, busulfan, and melphalan for autologous stem-cell transplant in patients with relapsed or refractory myeloma: a phase 2 trial and matched-pair comparison with melphalan.高剂量吉西他滨、白消安和马法兰用于复发或难治性骨髓瘤患者的自体干细胞移植：一项2期试验及与马法兰的配对比较
Lancet Haematol. 2017 Jun;4(6):e283-e292. doi: 10.1016/S2352-3026(17)30080-7. Epub 2017 May 15.
4
Phase I study of cord blood-derived natural killer cells combined with autologous stem cell transplantation in multiple myeloma.脐带血来源的自然杀伤细胞联合自体干细胞移植治疗多发性骨髓瘤的I期研究
Br J Haematol. 2017 May;177(3):457-466. doi: 10.1111/bjh.14570. Epub 2017 Mar 14.
5
Cytotoxic efficacy of filanesib and melphalan combination is governed by sequence of treatment in human myeloma cells.非那西布与美法仑联合用药对人骨髓瘤细胞的细胞毒性作用受治疗顺序的影响。
Blood Cancer J. 2016 Oct 7;6(10):e480. doi: 10.1038/bcj.2016.92.
6
Outcome of Patients with Multiple Myeloma and CKS1B Gene Amplification after Autologous Hematopoietic Stem Cell Transplantation.多发性骨髓瘤和CKS1B基因扩增患者自体造血干细胞移植后的结局
Biol Blood Marrow Transplant. 2016 Dec;22(12):2159-2164. doi: 10.1016/j.bbmt.2016.09.003. Epub 2016 Sep 13.

本文引用的文献

1
High-dose chemotherapy plus autologous stem-cell transplantation as consolidation therapy in patients with relapsed multiple myeloma after previous autologous stem-cell transplantation (NCRI Myeloma X Relapse [Intensive trial]): a randomised, open-label, phase 3 trial.高剂量化疗联合自体造血干细胞移植作为既往自体造血干细胞移植后复发多发性骨髓瘤患者的巩固治疗（NCRI 骨髓瘤 X 复发[强化试验]）：一项随机、开放标签、3 期试验。
Lancet Oncol. 2014 Jul;15(8):874-85. doi: 10.1016/S1470-2045(14)70245-1. Epub 2014 Jun 16.
2
Novel agents for multiple myeloma to overcome resistance in phase III clinical trials.用于多发性骨髓瘤的新型药物在 III 期临床试验中克服耐药性。
Semin Oncol. 2013 Oct;40(5):634-51. doi: 10.1053/j.seminoncol.2013.07.007.
3
Salvage autologous stem cell transplantation for multiple myeloma relapsing or progressing after up-front autologous transplantation.补救性自体干细胞移植治疗一线自体移植后复发或进展的多发性骨髓瘤。
Leuk Lymphoma. 2013 Oct;54(10):2200-4. doi: 10.3109/10428194.2013.773998. Epub 2013 Mar 4.
4
Autologous stem cell transplantation: an effective salvage therapy in multiple myeloma.自体干细胞移植：多发性骨髓瘤的有效挽救治疗方法。
Biol Blood Marrow Transplant. 2013 Mar;19(3):445-9. doi: 10.1016/j.bbmt.2012.11.013. Epub 2012 Nov 24.
5
Bortezomib with high dose melphalan conditioning for autologous transplant is safe and effective in patients with heavily pretreated and high risk multiple myeloma.硼替佐米联合大剂量马法兰预处理方案用于自体移植治疗预处理充分且高危的多发性骨髓瘤患者安全且有效。
Leuk Lymphoma. 2013 Jul;54(7):1465-72. doi: 10.3109/10428194.2012.746682. Epub 2012 Dec 14.
6
Durable remission with salvage second autotransplants in patients with multiple myeloma.在多发性骨髓瘤患者中，挽救性二次自体移植可实现持久缓解。
Cancer. 2012 Jul 15;118(14):3549-55. doi: 10.1002/cncr.26662. Epub 2011 Nov 15.
7
Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study.来那度胺和硼替佐米治疗后复发的多发性骨髓瘤的进展和生存风险：一项多中心国际骨髓瘤工作组研究。
Leukemia. 2012 Jan;26(1):149-57. doi: 10.1038/leu.2011.196. Epub 2011 Jul 29.
8
Lenalidomide, cyclophosphamide and dexamethasone (CRd) for newly diagnosed multiple myeloma: results from a phase 2 trial.来那度胺、环磷酰胺和地塞米松（CRd）用于新诊断的多发性骨髓瘤：来自 2 期试验的结果。
Am J Hematol. 2011 Aug;86(8):640-5. doi: 10.1002/ajh.22053. Epub 2011 May 31.
9
Lenalidomide (Revlimid) combined with continuous oral cyclophosphamide (endoxan) and prednisone (REP) is effective in lenalidomide/dexamethasone-refractory myeloma.
Br J Haematol. 2010 Jan;148(2):335-7. doi: 10.1111/j.1365-2141.2009.07931.x.
10
International uniform response criteria for multiple myeloma.多发性骨髓瘤的国际统一反应标准。
Leukemia. 2006 Sep;20(9):1467-73. doi: 10.1038/sj.leu.2404284. Epub 2006 Jul 20.